Investing
Encysive Pharmaceuticals (ENCY): Another Microcap Biopharma Implodes
Published:
U.S. regulators again declined to approve its drug Thelin as a treatment for a life-threatening lung disease. Encysive (ENCY) said it may have to cut costs and staff.
The company’s shares took at 50% haircut, and fell as low at $1.85. The company’s 52-week high is $7.21. Encysive’s market cap has dropped to $154 million.
The event highlight the dangers of investing in tiny "one trick pony" biopharma companies. In Q1, the company had sales of $5.4 million and an operating loss of $28.7 million.
With current cash on hand at $52.7 million and a large debt load, the company does not appear to have much time to improve its future prospects.
Douglas A. McIntyre
Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE
Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply
clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
